Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine

/in , , , , /by

This powerpoint presentation explains the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine. It contains several graphs to display the potential benefits and harms of people by age and risk; they clearly show that despite the potential risks of the vaccine, complications from COVID-19 are far worse.

Source: Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine

    Views 971

    Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

    /in , , , /by

    Identifying and understanding COVID-19 vaccine hesitancy within distinct populations may aid future public health messaging. Using nationally representative data from the general adult populations of Ireland and the United Kingdom, we found that vaccine hesitancy/resistance was evident for 35% and 31% of these populations respectively. Vaccine hesitant/resistant respondents in Ireland and the UK differed on a number of sociodemographic and health-related variables but were similar across a broad array of psychological constructs.

    Source: Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

      Views 794

      COVID-19: Long Term Health Effects

      /in , /by

      This guidance from Public Health England explains that around 10% of mild coronavirus (COVID-19) cases who were not admitted to a hospital have reported symptoms lasting more than 4 weeks. A number of hospitalized cases reported continuing symptoms for 8 or more weeks following discharge.

      It suggests that patients recovering from COVID-19 infection should speak to their family doctor about local care pathways for support and assessment of any long-term symptoms or health problems.

      Source: COVID-19: Long Term Health Effects

        Views 794